A variety of factors cooperate to regulate neovessel formation and persistence. Proangiogenic growth factors have remained an area of intense interest due to their capacity to promote endothelial cell (EC) proliferation and to initiate the angiogenic program. These growth factors are associated with increased cell survival, yet paradoxically, angiogenic ECs are more susceptible to apoptosis than quiescent ECs. Survival is regulated by cooperation between growth factor receptors and integrins, which are in turn governed by the composition of the local extracellular matrix (ECM). Integrin-mediated signaling is altered or disrupted by the presence of soluble, rather than matrix-bound ligands, thus providing a means by which ECM remodeling can influence both integrinand growth factor-mediated events. Ultimately, the collaboration of these factors determines whether ECs survive or die, thereby regulating neovascularization.
The growth of new blood vessels plays a critical role in physiological (and developmental) processes, but is also central to the progression of many diseases. Disorders such as cancer and inflammatory disease exploit angiogenesis as a means to support expanding tumor and aberrant tissue growth, respectively. Angiogenesis contributes to other pathologies, including diabetic retinopathy, macular degeneration, and endometriosis. However, many endogenous antiangiogenic factors have now been isolated, suggesting that angiogenesis is a tightly controlled process regulated by the relative quantities of proangiogenic and antiangiogenic factors (Folkman, 1995) . Although pathological angiogenesis is a rare event, the degree of neovascularization associated with disease is often a diagnostic and/or prognostic indicator of disease progression (Craft and Harris, 1994; Gasparini et al., 1998) .
During physiological forms of angiogenesis, the balance of proangiogenic and antiangiogenic factor production changes as angiogenesis progresses. Proangiogenic factors initially favor the initiation of endothelial proliferation and invasion; however, these signals are attenuated by the subsequent generation of antiangiogenic factors (many produced by the endothelial cells themselves). This is best exemplified during the final phase of angiogenesis, a process termed 'vascular pruning', in which endothelial cells (ECs) that have failed to mature are eliminated (Keshet and Ben-Sasson, 1999) .
Angiogenic ECs are more susceptible to apoptosis than their quiescent counterparts (Brooks et al., 1994; Kerbel et al., 2000) . The continued survival of angiogenic ECs is intimately tied to their local microenvironment and, in particular, the presence of survivalpromoting growth factors and extracellular matrix (ECM) proteins. De novo protein synthesis/secretion, deposition of ECM from plasma, and liberation of protein fragments and growth factors from pre-existing ECM by proteases contribute to the dynamic restructuring of the vascular microenvironment during angiogenesis. Blockade of these events can be sufficient to induce apoptosis and block an angiogenic response. For example, agents which disregulate growth factor receptor-or adhesion receptor-mediated signaling events can induce apoptosis in angiogenic ECs (Brooks et al., 1994; Witte et al., 1998; Klement et al., 2002) . It is worth noting that these interventions actively induce apoptosis in the ECs, rather than simply suppressing the induction (or execution) of proliferative or invasive events required for angiogenesis. Thus, it appears that apoptosis naturally regulates angiogenesis in vivo, acting as the principle mechanism for 'vascular pruning' (Keshet and Ben-Sasson, 1999) . Pruning can occur in a fraction of neovessels, or all of them, since some neovascularization events are transient in nature. A good example of this is neovascularization induced very rapidly by the vascular endothelial growth factor (VEGF) during follicle-associated angiogenesis in the ovary. Concomitant ECM alterations and ovum release coincide with an abrupt halt to VEGF production, the termination of angiogenesis, and complete vascular regression via apoptosis (Dickson et al., 2001) . Developmental angiogenesis occurring during lens formation in the mammalian eye proceeds in a similar manner (Mitchell et al., 1998) . In contrast, many angiogenic events are permanent and, in these cases, many vessels remain unaffected by 'vascular pruning'. The persistence of these neovessels at the 'conclusion' of angiogenesis is related to the duration of stimulus as well as other cues that govern the maturation (or differentiation) of the vessels (Hirschi and D'Amore, 1997; Abramovitch et al., 1998) .
Observations in these physiological systems, where transient angiogenic events occur in response to brief stimulation with cytokines, offer insight into the design of angiogenesis-based therapies. For example, they may explain why collateral vessel growth in the heart, liver or tumor models initiated by VEGF require the sustained presence of VEGF. Although transient exposure to VEGF will rapidly induce the formation of an immature vessel network, these neovessels will regress upon growth factor withdrawal. By contrast, sustained VEGF stimulation can promote vessel maturation, allowing vessels to persist if VEGF is eventually withdrawn (Dor et al., 2002) . These results suggest that, during physiological angiogenesis, the duration of the stimulus can act to influence the permanency of the response. This may occur directly, if the continued presence of growth factors is a prerequisite for EC maturation. However, it is perhaps more likely that these growth factors act to promote survival while secondary maturation factors, such as angiopoietins and/or pericytes, accumulate.
Hox genes and the angiogenic program
Why do angiogenic cells suddenly become susceptible to apoptotic stimuli, while nearby quiescent cells are not? The answer is most likely linked to changes in the gene expression profiles of the cells involved. Angiogenesis initiated by growth factors (or by proangiogenic ECM components) results in the activation of homeobox (Hox) master genes that are essential in activating secondary endothelial gene transcription events. Stimulation with angiogenic growth factors results in the induction of HoxD3, which subsequently upregulates the expression of a panel of genes promoting cell invasion, including matrix metalloproteinases (MMPs), integrin avb3, and UPA (Boudreau et al., 1997) (Figure 1 ). The formation of 'immature vessels' from invasive vascular sprouts requires a second Hox gene, HoxB3, which promotes lumen formation within the sprouts via transcription of differentiation factors such as ephrin A1 (Myers et al., 2000) . The proliferative ECs that form the sprouts and neovessels are sensitive to apoptotic cues, such as disruption of the cell-ECM contact or elimination of growth factors.
In contrast with EC, maturation and the restoration of quiescence are associated with re-expression of Hox D10, a master gene present in pre-existing quiescent vessels but absent from the 'activated' angiogenic endothelium. HoxD10 expression leads to quiescence through several mechanisms, including downregulation of invasive gene expression, competition with HoxD3 for 'common' transcription cofactors (leading to Figure 1 Responsiveness to apoptotic cues among angiogenic ECs. The stimulation of Ecs with angiogenic growth factors results in alterations in EC biology, including increased proliferation, altered integrin expression, and the transcription of gene products that act to remodel the local ECM. Invasive ECs (upper left) as well as immature neovessels (upper right) are sensitive to stimuli which induce apoptosis (brown fill). In contrast, pre-existing blood vessels (lower left) as well as neovessels which complete maturation at the conclusion of angiogenesis (lower right) become quiescent (yellow fill) and display increased resistance to proapoptotic stimuli Figure 2 Interacting factors influence EC survival during angiogenesis. The capacity of ECs to survive during tissue invasion is regulated by factors acting locally during angiogenesis. Remodeling of the local ECM required for invasion involves the production of soluble protein such as thrombospondins, as well as proteolytic cleavage of matrix proteins. The protein fragments generated during this process can promote EC apoptosis. Opposing this, new provisional ECM is produced locally, or deposited from plasma. The deposited ECM bound by integrins acts as a survival factor, both by limiting the impact of proapoptotic agents (such as death ligands) as well as potentiating EC responses to growth factors. Growth factors themselves have somewhat differing effects on EC resistance to apoptosis, and cooperate with ECM-bound integrins to promote cell survival. In addition, cell-cell contacts appear to act similarly to ECM ligation, promoting resistance to apoptotic stimuli downregulation of avb3), and transcription of gene products that block invasive cell behavior, such as the MMP inhibitors (Myers et al., 2002) . These quiesced ECs appear to be most likely to survive vascular pruning at the conclusion of angiogenesis.
Multiple factors influence apoptosis in angiogenic ECs
It is not yet clear whether EC apoptosis during the conclusion of angiogenesis results from the induction of death by a proapoptotic factor, or by the absence of a protective (survival) factor. The situation becomes more complicated when one considers that the action of proapoptotic factors is balanced by the presence of survival factors (Figure 2 ). Therefore, it is perhaps not surprising to learn that EC death or survival is influenced by diverse factors, including angiogenic cytokines, local remodeling of the ECM, inflammation, and exposure to local stresses such as sustained hypoxia or chemotherapeutic agents.
The fact that so many factors balance the decision between life and death in angiogenic ECs has given rise to the theory that interventions which impact any single factor strongly enough will be sufficient to generally 'tip the balance' towards EC apoptosis (Folkman, 1995) . However, despite dramatic results in a variety of preclinical models, antiangiogenic agents have so far met with limited success in the clinic. In part, this may be due to the fact that human tumors arise spontaneously, and thus are 'selected' for their ability to establish equilibrium between ECM remodeling, growth factor production, and survival of the local vasculature. However, it is also likely that the multiple proangiogenic growth/survival factors produced by human tumors may provide a level of redundancy. Thus, therapies that target a single growth factor pathway or receptor may demonstrate initial effect, but may become less effective as a tumor 'switches' (i.e. is selected for the capacity to produce different) arrays of angiogenic cytokines produced. This selection process may be augmented, at least in part, by deposition of survival factors such as ECM proteins, which can sustain cellular viability in response to a wide array of antiangiogenic insults (Meredith et al., 1993; Isik et al., 1998; Malyankar et al., 2000; Aoudjit and Vuori, 2001) . Thus, in the temporary absence of appropriate growth factors, the ECM may act as an interim survival factor, allowing ECs to persist until the next wave of angiogenic factors is produced. The presence of an inappropriate ECM does not promote EC survival under these stresses, and, in fact, may even promote apoptosis (see below).
ECM as a principle regulator of apoptosis
Receptors for the ECM, in particular the integrins, act not only to provide anchorage for ECs, but also provide information about the ECs' local microenvironment that facilitates the cell's decision to proliferate, migrate or die. Integrin expression on ECs changes upon stimulation with proangiogenic growth factors, suggesting that they play an integral role in the angiogenic program (Brooks et al., 1994) . Integrin ligation is required for cellular responses to most angiogenic growth factors (Eliceiri, 2001) , suggesting that the local ECM composition/remodeling will orchestrate EC responses, including apoptosis (Jones et al., 1993) .
Perhaps, the most dramatic upregulation of any integrin during angiogenesis occurs with the integrin avb3, which is not expressed on quiescent blood vessels (Brooks et al., 1994) . Integrin avb3 is not commonly expressed in other tissues, and, with the exception of some hematopoietic (or hematopoietic-derived) cells, is generally absent in adult organisms. Integrin avb3 has been linked to cell migration and invasion (FeldingHabermann and Cheresh, 1993) . However, integrin avb3 also appears to play a critical role in mediating cell survival. In particular, integrin avb3 ligation has been linked to signaling via the NF-kB survival pathway (Malyankar et al., 2000) , and agents that block avb3 binding to the ECM will also promote apoptosis among angiognic ECs in vitro and in vivo (Brooks et al., 1994; Brassard et al., 1999) . These results suggest that avb3 may be a critical regulator of EC survival.
Interestingly, a population of Iraqi Jews lacking functional avb3 demonstrate a platelet defect but no vascular phenotype (Coller et al., 1991) , while mice lacking integrin avb3 expression have apparently normal angiogenesis (Hodivala-Dilke et al., 1999) . These results suggest that either avb3 is not required as a survival factor during angiogenesis, or, in its absence, a compensating or redundant mechanism is initiated. Moreover, during chronic pathologies such as tumor growth, increased angiogenesis is observed in mice lacking expression of avb3 (Reynolds et al., 2002) , suggesting that avb3 expression may not promote angiogenesis, but rather may act in the negative regulation of angiogenesis, especially during reiterative (i.e., chronic) angiogenic processes.
Integrins as dependence receptors
Recent findings suggest that integrins can act as dependence receptors (Stupack et al., 2001) . For example, integrin avb3 (among others) can promote cell death when unligated, or 'ligated' by soluble (in contrast to ECM-immobilized) antagonists, both in vitro and in vivo (Brooks et al., 1994; Brassard et al., 1999; Storgard et al., 1999) . Integrin avb3 binds the widest array of ligands of any integrin (Cheresh, 1991) , and it is perhaps not surprising that a broad array of endogenous, soluble 'ligands' for avb3 are produced during angiogenesis (Figure 2 ). While some of these ligands are soluble native proteins such as thrombospondins (Chen et al., 2000) , others are protein fragments generated from preexisting ECM components such as collagens (endostatin, tumstatin) (O'Reilly et al., 1997; Maeshima et al., 2001) or the noncatalytic domains of the proteases themselves (angiostatin, PEX) (O'Reilly et al., 1994; Brooks et al., 1998) . However, the induction of apoptosis by soluble ligands (antagonists) is not a unique feature of integrin avb3. Antagonists of other integrins, such a5b1 and a2b1, can also efficiently promote EC apoptosis (Senger et al., 1997; Kim et al., 2000) . The relative impact of antagonism of these integrins on EC survival will relate to the level of expression of the integrin antagonized as well as the soluble ligands which impact that integrin. As noted, integrin avb3 is the target of a wide array of endogenous antagonists. This, together with the fact that integrin avb3 is selectively expressed only on angiogenic ECs, explains to a large degree the central role in angiogenesis attributed to integrin avb3 function.
In this respect, it is of significant interest that soluble integrin ligands induce apoptosis, while the same ligand, if immobilized within the ECM, promotes survival and even acts to preserve the viability of ECs induced to undergo apoptosis (Petitclerc et al., 2000; Rehn et al., 2001) . In this respect, integrins differ from most other classes of receptor, as they require cytosolic engagement of mechanical elements (i.e. actin assembly and contractility) for the so-called 'productive' signaling (Ingber, 1992) . Mechanical stimulation alone is sufficient to maintain integrin signaling (Ingber, 2002) , and integrinmediated signaling is maximized in cells undertaking mechanical activities, such as spreading or migrating on ECM (Schwartz and Ingber, 1994) . Conversely, disruption of the mechanical linkage can likewise compromise signaling from integrins (Meredith et al., 1993) , and ablation of integrin-mediated cell attachment triggers an array of proapoptotic mechanisms (reviewed in Frisch and Screaton, 2001). However, questions remain about the exact roles played by antagonized (or unligated) integrins that promote apoptosis.
Apoptotic pathways used by ECs in vivo
It is not yet clear which cell death pathways may be used by ECs (and under what circumstances), in vivo. Two principle caspase-dependent pathways exist in ECs; one triggered in response to death receptor ligation, termed the extrinsic apoptosis pathway, and a second triggered in response to mitochondrial changes that occur during stress, termed the intrinsic pathway. Unlike tumor cells, which may preferentially inactivate one or more apoptotic mechanisms, both pathways are available to mediate apoptosis in angiogenic ECs (Figure 3) .
The intrinsic pathway of apoptosis, induced by growth factor withdrawal or stresses, is blocked by integrin ligation, possibly by NkB activation (Scatena et al., 1998) and suppression of p53 activation (Stromblad et al., 1996) . Conversely, when EC apoptosis is initiated by soluble integrin antagonists (or ECM fragments), inhibitors of the extrinsic (or caspase 8/10-mediated) apoptotic pathway block death, while inhibitors of the intrinsic apoptotic pathway, or caspase 9-mediated pathway, are ineffective. In this case, integrin antagonism promotes the activation of caspase 8 (and apoptosis) among ECM-attached ECs in a PKAdependent manner (Stupack et al., 2001 ; Kim et al., 2002) . Importantly, antagonists of integrins avb3 and a5b1 appear to function principally by triggering apoptosis (and not by blocking cell migration), since pharmacological agents that block apoptosis rescue neovascularization in the presence of integrin antagonists. Considering these results, it becomes clear that mice lacking avb3 behave as one might expect, given that the ECs in these mice are unresponsive to avb3 antagonists (and therefore avb3-transmitted apoptotic cues). Moreover, observations in these mice suggest that the action of endogenous integrin antagonists may play a particularly important role during pathological forms of angiogenesis (Reynolds et al., 2002) .
In contrast with the results implicating caspase 8, caspase 9 does not appear to be essential for vascular pruning, at least during developmental angiogenesis, as no general vascular phenotype is reported in the caspase 9 KO mice (Kuida et al., 1998) . Nevertheless, suppression of the caspase 9 death pathway could still be important in pathological forms of angiogenesis, and correlations have been made between EC survival and expression/activity of p53 (Stromblad et al., 1996) , mTor (Maeshima et al., 2000) , bcl-2 family proteins Figure 3 Influence of integrin ligation on caspase-mediated death pathways in ECs. ECs can undergo apoptosis via either the extrinsic death pathway, initiated by surface-receptor-mediated activation of caspase 8 (such as that by death receptors or unligated/antagonized integrins -left side), or via the intrinsic pathway mediated by mitochondrial release of elements that activate caspase 9 in response to cell stress (right side). Caspase 8 activation can also trigger mitochondrial release of effectors, leading to caspase 9 activation and apoptosis via the 'type II' extrinsic pathway (not shown). All pathways result in the downstream activation of executioner caspases (caspase 3 is shown) leading to cell death, and each is influenced by ECM ligation. The intrinsic pathway is suppressed by integrin-mediated adhesion that leads to alterations in the abundance and activity of regulatory proteins such as the bcl-2 'gatekeeper' proteins, c-FLIP (an inhibitor of caspase 8 activation), and several of the IAP proteins that block apoptosis by direct binding of caspase 3 and/or caspase 9 (Matter and Ruoslahti, 2001) , and cell cycle inhibitors (Plath et al., 2000) , all of which function to block caspase 9 activation. Similarly, antagonists of integrin avb3 suppress retinal neovascularization in p53wt animals, yet have little antiangiogenic activity in p53À/À animals (Stromblad et al., 2002) . As p53 is generally assumed to be involved selectively in the regulation of the intrinsic apoptosis cascade, these data implicate caspase 9, rather than caspase 8, in EC apoptosis in the retina.
The role of p53 in EC survival remains somewhat confusing. For example, p53 activity opposes the induction of apoptosis by rapamycin via mTOR (Huang et al., 2001) , and mTOR has been suggested to be a downstream target of integrin antagonists in ECs in vitro. (Maeshima et al., 2000) Thus, if mTOR is a bona fide target of integrin antagonists, one might expect that deletion of p53 should increase sensitivity to integrin antagonists. Conversely, angiogenesis in p53-deficient mice is resistant to the effects of integrin antagonists (Stromblad et al., 2002) . Similarly, cells expressing activated protein kinase Akt, which also opposes p53 function (Mayo and Donner, 2002) , demonstrate increased sensitivity to mTOR inhibitors (Neshat et al., 2001; Yu et al., 2001) , while 'active' Akt rescues EC survival in the presence of integrin antagonists (Maeshima et al., 2002) . However, active Akt blocks the apoptosis initiated by caspase 8 (Suhara et al., 2001; Li et al., 2002) or caspase 9 (Frisch and Screaton, 2001) pathways, and these studies with Akt may therefore be difficult to interpret. An additional 'complication' to the interpretation of the role of p53 in EC survival during angiogenesis is the finding that p53 may bind within a 600 kDa þ macrocomplex that includes caspase 8 (Ding et al., 2000) . Since p53 has been reported to have proapoptotic activities independent of its transcriptional activities (which activate the intrinsic apoptosis pathway), it will be interesting to determine whether p53 also influences the extrinsic apoptosis pathway during angiogenesis.
Integration of death and survival signaling events during angiogenesis
The observation that the genetic deletion of any single EC integrin does not prevent angiogenesis (with the exception of integrins a5 and b1, which are required for viability of the embryo) (Bouvard et al., 2001 ) fits well with our knowledge of how integrins signal (Giancotti and Ruoslahti, 1999) . ECs express eight or nine different integrin heterodimers, which engage a broad range of ECM components. Loss of a single integrin (e.g., avb3) would not be expected to compromise endothelial cell adhesion, per se. Nor is it necessary to suggest 'compensation,' or positive signaling by other integrins in the 'absence' of b3, since many integrins are capable of independently activating common signaling pathways (Giancotti and Ruoslahti, 1999) . Most integrin heterodimers are capable of activating focal adhesion kinase (FAK) or Shc (or both), as well as downstream elements including Ras, Raf-1, Mek1, and the MAP kinases Erk1 and Erk2. Signaling to Erk1/Erk2 is critical for angiogenesis, and inhibitors of MEK-1 block neovascularization (Eliceiri et al., 1998) . Erk activation facilitates proliferation and cellular migration; however, it also protects cells from many forms of apoptosis (Cho and Klemke, 2000; Howe et al., 2002) .
Integrins can also signal to the phosphoinositide 3 0 kinase (PI3K) pathway, leading to activation of Akt and Rho family GTPases (Giancotti and Ruoslahti, 1999) . In particular, activation of Akt (by mutation of loss of the regulatory phosphatase PTEN) allows some transformed cell types to remain viable in an anchorageindependent manner (Frisch and Screaton, 2001), likely due to its capacity to block both pathways of apoptosis, described above. Integrin ligation also leads to the activation of FAK (Schlaepfer et al., 1999) . FAK activation occurs upstream of Erk and PI3K, and is likely to account for at least a portion of the ability of integrins to suppress p53-mediated apoptosis. FAKdeficient mouse embryos die early (Ilic et al., 1995) , and cells derived from FAKÀ/À mice can only be cultured in a p53-deficient background, despite the fact that these cells still activate Erk and PI3K pathways (Schlaepfer et al., 1999) . Interestingly, dominant-negative forms of FAK, such as FRNK, can also either induce apoptosis or predispose cells to apoptosis initiated by other means. Interestingly, many of the pathways activated by integrins (Src, PI3K, Erk) are also activated by proangiogenic cytokines such as bFGF and VEGF in ECs (Eliceiri, 2001) . It has become apparent that ligated integrins may establish signaling partnerships with specific growth factor receptors. Thus, integrins and growth factor receptors likely play complementary roles in initiating the angiogenic program and in cell survival. For example, although antagonism of integrin avb3, or a5b1, can induce apoptosis during angiogenesis induced by bFGF, they have dramatically reduced the effect on angiogenesis induced by VEGF (Friedlander et al., 1995) . Interestingly, the protection afforded by VEGF signaling is itself dependent upon ligation of another integrin, in this case avb5. Blockade of integrin avb5, an integrin which does not appear to be proapoptotic (Stupack et al., 2001) , nevertheless disrupts VEGFmediated signaling to Src and Erk (Eliceiri et al., 2002) .
The capacity of VEGF to protect against integrin avb3 antagonism, which bFGF lacks, is interesting given that these growth factors can activate common downstream signaling cascades. In fact, both activate Src, Ras, and the PI3K and Erk cascades (Ferrara, 2002) . Among these pathways, the activation of Erk1/Erk2 is critical for angiogenesis, since inhibition of MEK (Eliceiri et al., 1998) or Raf blocks agreement angiogenesis induced by either growth factor. Therefore, it is likely that protection from antagonists will be attributed to upstream signaling events parallel to, or required for, the activation of the Erk pathway, which are unique to VEGF signaling.
For example, although Src is activated by both VEGF and bFGF, only VEGF-induced angiogenesis is dependent upon Src kinase activity (Eliceiri et al., 2002) . In this case, it appears that Src is critical for formation of the integrin avb5/FAK complex necessary for signaling downstream of VEGFR2 (Eliceiri et al., 2002) . Mice lacking avb5 have impaired responses to VEGF (Eliceiri et al., 2002) , although angiogenesis appears to proceed normally. It is not yet clear whether VEGF provides protection against apoptosis induced by avb3 integrin antagonists in these mice.
ECM influences cell responses to other apoptotic triggers
Current data underscore the importance of the ECM as a critical survival factor for ECs in vivo. The data are less clear on the role of death receptors and their ligands. While it appears that Fas and FasL regulate angiogenesis in the retina of adult animals (Kaplan et al., 1999) , it is clear that soluble FasL can also induce an inflammatory angiogenesis in Matrigel plugs in vivo (Biancone et al., 1997) . Similarly, TNFa induces angiogenesis in vivo (Friedlander et al., 1995) , and may contribute to inflammatory angiogenesis, such as that seen in rheumatoid arthritis (Walsh and Pearson, 2001) . Activated ECs express greater levels of death receptors than quiescent ECs (Volpert et al., 2002) , but are generally resistant to apoptosis mediated by death ligands in vitro. This may be due to the production of survivalpromoting cytokines, such as VEGF, the presence of an immobilized ECM, or both. Accordingly, agents which modulate ECM-binding properties of ECs also render them susceptible to death ligand signaling (Ruegg et al., 1998; Aoudjit and Vuori, 2001; Volpert et al., 2002) . The actions of both ECM and death ligands may be somewhat different in vivo. In contrast to soluble integrin ligands, soluble death ligands, produced by proteolysis, are far less efficient at inducing apoptosis than immobilized death ligands (Mitsiades et al., 2001) . The actions of proteases present during angiogenesis may therefore be protective against death ligand signaling. However, the generation of soluble ECM fragments may compensate by compromising integrin-mediated prosurvival functions, or even inducing apoptosis directly through integrins themselves.
EC precursors
Recent studies suggest that a significant fraction of ECs, both in physiological and pathological forms of angiogenesis, are derived from circulating endothelial precursor cells (CEPs). While it is not yet clear how the survival of CEPs is regulated during angiogenesis, it is assumed that these cells do not require adhesion during circulation for survival. Integrin-mediated events may be critical for targeting and activating these cells, at which point it is likely that they become dependent upon the underlying ECM as a survival factor (just as other angiogenic ECs are) (Salven et al., 2003) . It is also possible that sensitivity to apoptosis is gained as part of the 'precursor to EC' differentiation process, since a requirement for ECM interaction during this process has been proposed to occur during this process in vitro and in vivo (Moldovan, 2003) .
Conclusions and therapeutic outlook
Angiogenesis involves the programmed dedifferentiation of pre-existing ECs (and possibly the recruitment of CEPs) allowing proliferation and tissue invasion. However, as a part of this process, ECs become susceptible to apoptosis, requiring growth factor stimulation and integrin-mediated engagement of immobilized ECM components to maintain viability. Different integrins appear to be tied to signaling through distinct growth factor receptors, suggesting that interventions which impact either the adhesion receptor or the growth factor receptor can impact angiogenesis. This appears to be a natural process, as a variety of different proteins and protein fragments produced during angiogenesis milieu act as endogenous soluble ligands (antagonists) of integrins. Since apoptosis occurs in these vessels during physiological forms of angiogenesis, it is tempting to speculate that these soluble integrin antagonists may represent a natural homeostatic mechanism that governs the behavior of invasive ECs, providing a 'self-limiting' mechanism to prevent excessive or aberrant neovascularization (perhaps even acting as an innate mechanism to limit pathological forms of angiogenesis). In fact, tumor vessels exhibit spontaneous regression, although this effect is generally offset by concomitant induction of new angiogenic processes.
The initial promise of antiangiogenic therapies may ultimately become a reality. Since ECs are genetically stable relative to tumor cells, they are far less likely to acquire resistance to endogenous or chemotherapeutic agents. In contrast to tumor cells, which often inactivate one (or both) major apoptotic pathway, ECs have both intrinsic and extrinsic apoptotic pathways intact. Moreover, the architecture of the vasculature actually promotes collateral effect, as EC death and vessel collapse in turn promote the apoptosis of 'downstream' ECs and dependent tumor and stromal cells (Folkman and Hanahan, 1991) . However, we have only now begun to understand the molecular interactions that regulate EC apoptosis, and an increased understanding will be necessary before it can be manipulated with certainty.
